---
title: "EU Approves Allergan Aesthetics' Boey For Treatment Of Frown Lines"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293035707.md"
description: "Allergan Aesthetics, a subsidiary of AbbVie, announced that the European Commission has approved Boey for the temporary improvement of moderate to severe glabellar lines in adults. Boey is the first and only botulinum neurotoxin serotype E approved in Europe, showing an onset of effect as early as eight hours with results lasting two to three weeks. This follows its approval in Canada in June."
datetime: "2026-07-17T12:22:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293035707.md)
  - [en](https://longbridge.com/en/news/293035707.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293035707.md)
---

# EU Approves Allergan Aesthetics' Boey For Treatment Of Frown Lines

Add  as your preferred news source on Google

 Add Now

Allergan Aesthetics, part of AbbVie (ABBV), on Friday said the European Commission approved Boey for the temporary improvement of moderate to severe glabellar lines, or frown lines between the eyebrows, in adults.

The company said Boey is the first and only botulinum neurotoxin serotype E approved in Europe. In clinical studies, the treatment showed an onset of effect as early as eight hours after injection, with results lasting two to three weeks.

Boey also received approval in Canada in June.

AbbVie shares closed 4.21% higher at $254.39 on Thursday.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial](https://longbridge.com/en/news/293659753.md)
- [7,295 Shares in AbbVie Inc. $ABBV Acquired by Kiley Juergens Wealth Management LLC](https://longbridge.com/en/news/291953575.md)
- [Nektar Therapeutics announces press release on start of Phase 3 ZENITH AD program for rezpegaldesleukin in atopic dermatitis](https://longbridge.com/en/news/293330379.md)
- [Sagimet to advance denifanstat Phase 3 in US; $104.5M cash, $175M offering funds operations through 2028](https://longbridge.com/en/news/293324312.md)
- [Arrowhead Pharma announces press release on plozasiran Phase 3 SHASTA-3 and SHASTA-4 topline results](https://longbridge.com/en/news/293466237.md)